By James A. Loyola

Listed healthcare technology company Philab Holdings Corporation is planning to acquire 67 percent of local pharmaceutical firm Sydenham Laboratories, Inc. (SLI).

With more than 40 years in the industry, SLI is the country’s only manufacturer of hormone- based drugs and specializes in oral drug preparation in dosage forms such as, tablet, capsule, syrup and powder for suspension.

SLI is known for their long line of drugs, with having over 300 certificates of product registration. Their line of business also includes production of food additives utilized for its added nutritional benefit and served in rural schools for less fortunate children.

SLI also offers a variety products focused on the central nervous system, endocrine system, cardiovascular system, and several medicines to cater the needs of its consumers.

“The acquisition of Sydenham Lab enables Philab Holdings to broaden our service offering to the Filipinos. SLI’s specialty in manufacturing pharmaceutical products will enhance our product services, especially in providing universal healthcare for the Filipinos and expanding the generics line,” said Philab Holdings Chairman Tom Navasero.

After this merger, Philab Holdings plans to launch a program in support of precision medicine that will enable both companies to maximize their synergies and prowess in the field of healthcare.

Navasero added that with this program, a new area of Pharmacogenomics will be developed, an innovation in healthcare technology which allows individuals to determine the most effective medication therapy treatment based on their genetic makeup.